These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37162160)

  • 1. Dopamine-Induced Oligomers of α-Synuclein Inhibit Amyloid Fibril Growth and Show No Toxicity.
    Galkin M; Topcheva O; Priss A; Borisova T; Shvadchak VV
    ACS Chem Neurosci; 2023 Jun; 14(11):2027-2034. PubMed ID: 37162160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of α-Synuclein Amyloid Fibril Elongation by Blocking Fibril Ends.
    Shvadchak VV; Afitska K; Yushchenko DA
    Angew Chem Int Ed Engl; 2018 May; 57(20):5690-5694. PubMed ID: 29575453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
    Bisaglia M; Tosatto L; Munari F; Tessari I; de Laureto PP; Mammi S; Bubacco L
    Biochem Biophys Res Commun; 2010 Apr; 394(2):424-8. PubMed ID: 20226175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
    Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
    Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally Designed Protein-Based Inhibitor of α-Synuclein Fibrillization in Cells.
    Priss A; Afitska K; Galkin M; Yushchenko DA; Shvadchak VV
    J Med Chem; 2021 May; 64(10):6827-6837. PubMed ID: 33970620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation.
    Hayden EY; Kaur P; Williams TL; Matsui H; Yeh SR; Rousseau DL
    Biochemistry; 2015 Aug; 54(30):4599-610. PubMed ID: 26161848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naphthoquinone-dopamine hybrids disrupt α-synuclein fibrils by their intramolecular synergistic interactions with fibrils and display a better effect on fibril disruption.
    Zhou Y; Yao Y; Yang Z; Tang Y; Wei G
    Phys Chem Chem Phys; 2023 May; 25(20):14471-14483. PubMed ID: 37190853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.
    Lam HT; Graber MC; Gentry KA; Bieschke J
    Biochemistry; 2016 Feb; 55(4):675-85. PubMed ID: 26799377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers.
    Vaikath N; Sudhakaran I; Abdi I; Gupta V; Majbour N; Ghanem S; Abdesselem H; Vekrellis K; El-Agnaf O
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Terminal Acetylation Affects α-Synuclein Fibril Polymorphism.
    Watson MD; Lee JC
    Biochemistry; 2019 Sep; 58(35):3630-3633. PubMed ID: 31424918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An α-synuclein decoy peptide prevents cytotoxic α-synuclein aggregation caused by fatty acid binding protein 3.
    Fukui N; Yamamoto H; Miyabe M; Aoyama Y; Hongo K; Mizobata T; Kawahata I; Yabuki Y; Shinoda Y; Fukunaga K; Kawata Y
    J Biol Chem; 2021; 296():100663. PubMed ID: 33862084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
    Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
    Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A RaPID Macrocyclic Peptide That Inhibits the Formation of α-Synuclein Amyloid Fibrils.
    Ikenoue T; Oono M; So M; Yamakado H; Arata T; Takahashi R; Kawata Y; Suga H
    Chembiochem; 2023 Jun; 24(12):e202300320. PubMed ID: 37186077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.
    Nors Perdersen M; Foderà V; Horvath I; van Maarschalkerweerd A; Nørgaard Toft K; Weise C; Almqvist F; Wolf-Watz M; Wittung-Stafshede P; Vestergaard B
    Sci Rep; 2015 May; 5():10422. PubMed ID: 26020724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
    Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
    Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability.
    Kaufmann TJ; Harrison PM; Richardson MJ; Pinheiro TJ; Wall MJ
    J Physiol; 2016 May; 594(10):2751-72. PubMed ID: 26915902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.